Physician profile
Daniel Brian Herring
NPI 1518089838
$7,006.61
in general payments reported to CMS, 2019-2025
29 companies · $1,644 in 2025
The $1,644 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $905 · 2020: $129 · 2021: $641 · 2022: $736 · 2023: $1,399 · 2024: $1,553 · 2025: $1,644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,160 · Education: $436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,159.87 |
| Education | $436.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,110.84 | 2019-2025 | |
| Journey Medical Corporation | $1,056.73 | 2019-2025 | |
| Janssen Biotech, INC. | $1,015.06 | 2019-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $860.59 | 2021-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $526.21 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $513.61 | 2020-2025 | Odomzo, Blu-U |
| Ucb, INC. | $296.18 | 2022-2025 | Bimzelx |
| Leo Pharma INC. | $278.44 | 2019-2025 | Adbry |
| Arcutis Biotherapeutics, INC. | $249.26 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $201.10 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $111.46 | 2019-2025 | Nemluvio, Aklief |
| Strata Skin Sciences, INC. | $96.73 | 2023-2025 | Xtrac |
| Amgen INC. | $95.50 | 2022-2024 | Otezla |
| Pfizer INC. | $87.35 | 2019-2021 | |
| Celgene Corporation | $84.34 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $58.53 | 2023-2024 | Xeomin |
| Lilly USA, LLC | $56.78 | 2021-2025 | Ebglyss, Taltz |
| Dusa Pharmaceuticals, INC. | $53.52 | 2019 | |
| Genentech USA, INC. | $38.10 | 2019-2021 | |
| Elekta, INC. | $34.36 | 2024 | Elekta Medical Linear Accelerator |
| Aclaris Therapeutics, INC. | $31.21 | 2019 | |
| Incyte Corporation | $26.39 | 2025 | Opzelura |
| Dermira, INC. | $24.91 | 2019 | |
| Genzyme Corporation | $22.33 | 2019 | |
| Organon LLC | $19.46 | 2025 | Vtama |
| Dermavant Sciences, INC. | $16.14 | 2024 | Vtama |
| Verrica Pharmaceuticals INC. | $15.29 | 2024 | Ycanth |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.37 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $12.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Herring listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.